Artelo Biosciences, Inc. · NASDAQ:ARTL
Artelo Biosciences — Investor Presentation (March 2018)
28 slides from Artelo Biosciences's investor presentation, March 2018
Slide 1: Company Presentation
US Phone: 760-943-1689 IRE Phone: +35314434604 Company Presentation E-mail: [email protected] March 2018 www.artelobio.com
Slide 2: Forward Looking Statements
Forward Looking Statements Statements in this Artelo Biosciences presentation that are not historical facts are "forward-looking statements" subject to risks/uncertainties. Such statements are based on current facts/analyses and other information that are based on forecasts of results, estimates of
Slide 3: Company
Artelo BIOSCIENCES
Slide 4: Company Overview: Introduction
Company Overview Introduction Company: Public quoted in the US Sector: Cannabinoid-based pharmaceuticals Focus: Endocannabinoid system modulation Therapeutic areas: Pain, Inflammation, Cachexia, Cardiovascular, Cancer Stock symbol: ARTL Exchange: OTC Liabilities: No debt US Headquarters: San Diego,
Slide 5: Leading Science
Leading Science 2e Artelo
Slide 6: Potential of the Endocannabinoid System (ECS)
Leading Science Potential of the Endocannabinoid System (ECS) “Modulating the ECS activity may have therapeutic potential in almost all diseases affecting humans, including obesity/metabolic syndrome, diabetes and diabetic complications, neuro-degenerative, inflammatory, cardiovascular, liver, gastr
Slide 7: Artelo's Approach to Modulating the ECS
Leading Science Artelo’s Approach to Modulating the ECS We are developing a portfolio of novel pharmaceuticals that address serious medical conditions Our programs are based on multiple mechanisms to target and modulate the ECS 7
Slide 8: Pipeline
Pipeline — Artelo
Slide 9: Full Spectrum ECS Modulation Pipeline
Pipeline Full Spectrum ECS Modulation Pipeline ART12.11 Novel CBD Composition Provisional patent filed in December 2017 claiming improved composition Cannabinoids Addresses physical polymorphism challenges with CBD Invented by Artelo scientists in collaboration with US-based top-tier CRO Pla
Slide 10: ART 12.11 Proprietary CBD Composition
ART 12.11 Proprietary CBD Composition
Slide 11: What is Cannabidiol (CBD)?
ART12.11 Proprietary CBD Composition What is Cannabidiol (CBD)? ▪ Second most abundant chemical found in the flowering bud of the cannabis plant ▪ Does not cause the same psychotropic effects as THC ▪ Has a multiple effects in the body: anti-inflammatory anti-oxidant anxiolytic analgesic a
Slide 12: Therapeutic Potential of Cannabidiol (CBD)
ART12.11 Proprietary CBD Composition Therapeutic Potential of Cannabidiol (CBD) Beyond current clinical use in multiple sclerosis and epilepsy, non-clinical evidence supports CBD’s potential for multiple therapeutic applications: Inducing tumor-cell specific cell death in vitro and in vivo in brea
Slide 13: ART12.11 Cannabidiol (CBD) Composition Superiority
ART12.11 Proprietary CBD Composition ART12.11 Cannabidiol (CBD) Composition Superiority What is so medicinally enticing about CBD? - There is strong evidence supporting CBD’s therapeutic activity - The WHO has designated CBD as safe* - Epidiolex (GWPH) PDUFA date: June 27, 2018** What opportunit
Slide 14: ART 26.12 FABP5 Inhibitor
ART 26.12 FABP5 Inhibitor
Slide 15: FABP5 and the Endocannabinoid System
ART26.12 FABP5 Inhibitor FABP5 and the Endocannabinoid System Overexpression of FABP5 increases the hydrolysis of anandamide (AEA) and FABP inhibition decreases AEA hydrolysis FABP5 inhibition increases AEA levels i.e. alternative mechanism to increase endocannabinoid tone (similar to FAAH inhib
Slide 16: FABP5 and Cancer
ART26.12 FABP5 Inhibitor FABP5 and Cancer ▪ FABP5 is upregulated in breast cancer (including triple-negative) and correlated with tumor grade and poor prognosis and FABP5 silencing decreases breast cancer cell growth and tumor growth in mouse models, and decreases epidermal growth factor receptor (E
Slide 17: ART26.12 Next Generation Endocannabinoid Modulator
ART26.12 FABP5 Inhibitor ART26.12 Next Generation Endocannabinoid Modulator ▪ ART26.12 is a highly-selective, highly-potent FABP5 inhibitor ▪ FABP5 inhibitors represent a novel and exciting mechanism of modulating the endocannabinoid system ▪ FABP5 inhibitors are likely candidates in pain and oncolo
Slide 18: ART 27.13 High-Potency Dual Agonist
ART 27.13 High-Potency Dual Agonist
Slide 19: Multiple Cancer Types are Sensitive to Cannabinoids
ART27.13 High-Potency Dual Agonist Multiple Cancer Types are Sensitive to Cannabinoids Literature CB1 and/or CB2 directed anti-tumour activity demonstrated in 1) ex-vivo, 2) in-vitro, 3) in-vivo, 4) human epidemiology 5) human clinical data Future Estimates for total worldwide sales in cancer types
Slide 20: Supportive Activity Data for CB1/CB2 Agonists as Anti-Tumor Agents
ART27.13 High-Potency Dual Agonist Supportive Activity Data for CB1/CB2 Agonists as Anti-Tumor Agents Synthetic cannabinoids have anti-tumor effects as a monotherapy CB1 Effect CB2 Effect Effects are blocked by cannabinoid antagonists Driven by both CB1 and CB2 effects >50% inhibitory effect
Slide 21: ART27.13 Advancing as an Anti-Cancer Agent
ART27.13 High=Potency Dual Agonist ART27.13 Advancing as an Anti-Cancer Agent Cachexia and treatment of cancer are both attractive opportunities A key focus will be understanding the novel anti-tumor potential We intend to fully explore cachexia with additional investment into supporting resea
Slide 22: Proven Leadership
Proven Leadership 22
Slide 23: Executive Management
Leadership Executive Management Gregory Gorgas, President & CEO Over 30 years of high-impact commercial and development experience as biotech veteran and entrepreneur, including global marketing leadership of Biogen’s worldwide cancer business, commercial officer at Mast Therapeutics with orphan dis
Slide 24: Scientific Advisors
Leadership Scientific Advisors Saoirse O’Sullivan, PhD Professor and noted researcher in development of cannabinoids for cancer, stroke, inflammation, and pain at the University of Nottingham, UK. Over 26 original research articles, 6 reviews and 3 book chapters on the topic of cannabinoid pharmacol
Slide 25: Board of Directors
Leadership Board of Directors Connie Matsui, Chair Serves on multiple pharmaceutical and nonprofit boards bringing executive leadership and general management expertise to her responsibilities. Chaired collaboration for the late stage development and commercialization of rituximab (MabThera/Rituxan)
Slide 26: Board of Directors
Leadership Board of Directors Georgia Erbez Currently CBO/CFO of Zosano Pharma. Formerly CFO at Raptor Pharmaceuticals during growth phase including first drug approval and commercial drug launch. Performed strategic consulting and financial management leadership for several public and private biote
Slide 27: Accomplishments and Highlights
Company Summary Accomplishments and Highlights 27
Slide 28: Contact
888 Prospect Street, Suite 210 29 Fitzwilliam Street Upper La Jolla, CA 92037 Dublin 2, Ireland Greg Gorgas (USA) 760.943.1689 Peter O’Brien (IRE) 083 140 6837 [email protected] www.artelobio.com [email protected]
Artelo Biosciences — Investor Presentation (March 2018) on 6ix